Clinical Trial Results:
Hyperbaric oxygen treatment in humans with Gram Positive Cocci endocarditis
Summary
|
|
EudraCT number |
2019-000857-29 |
Trial protocol |
DK |
Global end of trial date |
30 Jun 2022
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
15 Oct 2023
|
First version publication date |
15 Oct 2023
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
ENDOHOT
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT04691440 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Rigshospitalet
|
||
Sponsor organisation address |
Inge Lehmanns Vej 6, section 6011, Copenhagen N, Denmark, 2100
|
||
Public contact |
Hyperbaric Unit sect.4092, Rigshospitalet - University Hospital of Copenhagen, ole.hyldegaard@regionh.dk
|
||
Scientific contact |
Hyperbaric Unit sect.4092, Rigshospitalet - University Hospital of Copenhagen, 45 35454092, ole.hyldegaard@regionh.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
25 Oct 2022
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
30 Jun 2022
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
30 Jun 2022
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To assess feasibility including patient compliance of adding HyperBaric Oxygen Treatment (HBOT) to the standard management of patients with proven bacterial endocarditis.
|
||
Protection of trial subjects |
Feasability study, phaze II. Ethical approval, GCP monitoring and reporting to the Danish Medicines Agency.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Apr 2019
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 10
|
||
Worldwide total number of subjects |
10
|
||
EEA total number of subjects |
10
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
10
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
26 patients screened for inclusion diagnosed with endocarditis - gram positive cocci endocarditis. Of these 13 patients were excluded. 13 patients where enrolled into the HBOT protocol. | ||||||
Pre-assignment
|
|||||||
Screening details |
13 patients out of 26 screened excluded. | ||||||
Period 1
|
|||||||
Period 1 title |
2019-2022 (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Non-randomised - controlled
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
HBOT | ||||||
Arm description |
Adjuvant HBOT for endocarditis | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Conoxia
|
||||||
Investigational medicinal product code |
23390
|
||||||
Other name |
oxygen
|
||||||
Pharmaceutical forms |
Pressurised inhalation
|
||||||
Routes of administration |
Respiratory use
|
||||||
Dosage and administration details |
Hyperbaric oxygen. Delivered as inspiratory oxygen fraction of 1.0 at 245 kPa (- or 2.4 ATA, atmospheres absolute pressure) for 90 minutes.
|
||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
2019-2022
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Patient compliance
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Patient compliance
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
HBOT
|
||
Reporting group description |
Adjuvant HBOT for endocarditis | ||
Subject analysis set title |
Patient compliance
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Patient compliance
|
|
|||||||||||||
End point title |
Patient compliance [1] | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
2019-2022
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a feasibility study (phase II trial) where testing the practical adjuvant use of HBOT in patients with endocarditis is the primary focus. Sub-group analysis will provide statistiacal comparisons on patients paraclinical data before and after the intervention. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
Adverse events information
|
|||||||||||||||
Timeframe for reporting adverse events |
Non-serious AEs will be collected in the present study only during the HBOT-period. serious AEs is collected, registered in the CRFs and an assessment of causality performed.
|
||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||
Dictionary name |
GCP monitor | ||||||||||||||
Dictionary version |
1
|
||||||||||||||
Reporting groups
|
|||||||||||||||
Reporting group title |
ENDOHOT trial
|
||||||||||||||
Reporting group description |
- | ||||||||||||||
|
|||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |